In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioNTech gets $270mm in Series A round

Executive Summary

BioNTech AG (cancer immunotherapies and companion diagnostics) secured $270mm in Series A funding from lead investor the Redmile Group, Janus Henderson Investors, Invus, Fidelity Management & Research, and European family investors including the Struengmann Family Office. Struengmann and MIF Fond seeded BioNTech with $180mm back in 2008 when the company was formed.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies